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Objective
To identify patient characteristics, that predict the growth
retardation and to assess the risk/benefits proportion of
growth hormone (GH) treatment in JIA patients.
Methods
Study cohort was presented by 170 JIA patients (47 boys,
123 girls, mean age 12.1, disease duration 5.1 yrs).
Annual growth parameters were studied in relation with
premorbid and disease related factors. 30 prepubertal
patients, having the most significant delay of growing
were randomized in 2 groups. 15 patients were received
recombinant GH 0,05–0,07 mg/kg within 4–18 months;
other 15 patients were as control.
Results
Growth retardation was observed in 40% (height SDS ≤ -
2). It was associated with systemic variant (43.3% versus
13.4% in patients with normal height), disease duration
(7.9 ± 3.4 vs 6.3 ± 3.1 yrs), ESR levels (47.7 ± 14.8 vs 29.2
± 14.8), number of active joints, glucocorticosteroid treat-
ment independent of doses. Short stature in family cases
(19, 4% vs 2, 3%) and father's height SDS (-0,49 ± 0,1 vs
0,17 ± 0,4) obtained more often in patients with growth
retardation. There are no abnormality of GH secretion in
JIA patients. A significant response to GH treatment com-
pared with control group was seen in all children. The
median height velocity was 3.1 cm per 3 months (4–12.5
cm/1 year). We observed the disease increasing activity in
8/15 patients under GH therapy. Other complications
from GH-therapy were not marked.
Conclusion
We conclude that disease activity and genetic factors are
the most important reasons of growth retardation in JIA
patients. Recombinant GH may be of benefit in severe
growth retardation therapy, but can promote disease
activity.
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